Immunoassay for SARS-CoV-2 antibodies
AssigneePictor Limited
InventorsSandeep Kumar Vashist, Lionel Gilles Guiffo Djoko, Bhavesh Govind
Life of this patent
Estimating the term…
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.
Claims17
A method of detecting anti-SARS-CoV-2 antibodies from a sample from a subject comprising:
- contacting a substrate for surface plasmon resonance, localized surface plasmon resonance or interferometry detection of a plurality of target analytes with a biological sample from the subject, wherein the subject is suspected of having a SARS-CoV-2 infection or is or has been exposed to SARS-CoV-2;
- and
- detecting the presence of an anti-SARS-CoV-2 antibody, wherein the detection method is surface plasmon resonance, localized surface plasmon resonance or interferometry,
- wherein the substrate comprises an assay spot comprising at least two capture elements specific for SARS-CoV-2 printed on the substrate, each capture element corresponding to and being able to bind a target analyte, wherein the at least two capture elements are each a SARS-CoV-2 protein that binds to an antibody target analyte;
- and the SARS-CoV-2 protein is selected from the group consisting of a SARS-CoV-2 membrane protein (MP), nucleocapsid protein (NP), spike protein (SP), envelope protein (EP) and any combination thereof, and
- wherein the substrate is a porous membrane, a microtiter plate or a microparticle, thereby detecting anti-SARS-CoV-2.
A method for processing a microarray comprising:
- a) providing a substrate for surface plasmon resonance, localized surface plasmon resonance or interferometry detection of a plurality of target analytes, wherein the substrate comprises an assay spot comprising at least two capture elements specific for SARS-CoV-2 printed on the substrate, each capture element corresponding to and being able to bind a target analyte, wherein the at least two capture elements are each a SARS-CoV-2 protein that binds to an antibody target analyte;
- and the SARS-CoV-2 protein is selected from the group consisting of a SARS-CoV-2 membrane protein (MP), nucleocapsid protein (NP), spike protein (SP), envelope protein (EP) and any combination thereof, and wherein the substrate is a porous membrane, a microtiter plate or a microparticle;
- b) adding at least one sample to the substrate;
- and
- c) processing the substrate such that a detectable result is given by two or more of i) at least one fiduciary marker, ii) at least one positive colorimetric control, and iii) at least one positive control to monitor assay performance.
A substrate for surface plasmon resonance, localized surface plasmon resonance or interferometry detection of a plurality of target analytes comprising:
- (i) an assay spot comprising at least two capture elements specific for SARS-CoV-2 printed on the substrate, each capture element corresponding to and being able to bind a target analyte, wherein:
- the at least two capture elements are each a SARS-CoV-2 protein that binds to an antibody target analyte;
- and
- the SARS-CoV-2 protein is selected from the group consisting of a SARS-CoV-2 membrane protein (MP), nucleocapsid protein (NP), spike protein (SP), envelope protein (EP) and any combination thereof, and (ii) optionally one or more control spots comprising control elements selected from the group consisting of:
- a) at least one fiduciary marker,
- b) at least one negative control to monitor background signal,
- c) at least one negative control to monitor assay specificity,
- d) at least one positive colorimetric control,
- e) at least one positive control to monitor assay performance and any combination thereof,
- wherein the substrate is a porous membrane, a microtiter plate or a microparticle.
Dependencies are inferred from the claim text.